vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and CLARIVATE PLC (CLVT). Click either name above to swap in a different company.

CLARIVATE PLC is the larger business by last-quarter revenue ($585.5M vs $487.7M, roughly 1.2× CLOVER HEALTH INVESTMENTS, CORP.). CLARIVATE PLC runs the higher net margin — -6.9% vs -10.1%, a 3.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -1.4%). CLARIVATE PLC produced more free cash flow last quarter ($78.9M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -5.1%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Clarivate Plc is a British-American publicly traded analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business and market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. Clarivate calculates the impact factor of scientific journals, using data from its Web of Science product family, that also includes services...

CLOV vs CLVT — Head-to-Head

Bigger by revenue
CLVT
CLVT
1.2× larger
CLVT
$585.5M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+46.1% gap
CLOV
44.7%
-1.4%
CLVT
Higher net margin
CLVT
CLVT
3.2% more per $
CLVT
-6.9%
-10.1%
CLOV
More free cash flow
CLVT
CLVT
$147.9M more FCF
CLVT
$78.9M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-5.1%
CLVT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
CLVT
CLVT
Revenue
$487.7M
$585.5M
Net Profit
$-49.3M
$-40.2M
Gross Margin
67.2%
Operating Margin
-10.1%
5.2%
Net Margin
-10.1%
-6.9%
Revenue YoY
44.7%
-1.4%
Net Profit YoY
-123.2%
61.3%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
CLVT
CLVT
Q1 26
$585.5M
Q4 25
$487.7M
$617.0M
Q3 25
$496.6M
$623.1M
Q2 25
$477.6M
$621.4M
Q1 25
$462.3M
$593.7M
Q4 24
$337.0M
$663.0M
Q3 24
$331.0M
$622.2M
Q2 24
$356.3M
$650.3M
Net Profit
CLOV
CLOV
CLVT
CLVT
Q1 26
$-40.2M
Q4 25
$-49.3M
$3.1M
Q3 25
$-24.4M
$-28.3M
Q2 25
$-10.6M
$-72.0M
Q1 25
$-1.3M
$-103.9M
Q4 24
$-22.1M
$-191.8M
Q3 24
$-9.2M
$-65.6M
Q2 24
$7.4M
$-304.3M
Gross Margin
CLOV
CLOV
CLVT
CLVT
Q1 26
67.2%
Q4 25
66.8%
Q3 25
65.0%
Q2 25
67.2%
Q1 25
65.1%
Q4 24
65.7%
Q3 24
24.5%
66.2%
Q2 24
30.3%
67.2%
Operating Margin
CLOV
CLOV
CLVT
CLVT
Q1 26
5.2%
Q4 25
-10.1%
6.7%
Q3 25
-4.9%
7.1%
Q2 25
-2.2%
1.1%
Q1 25
-0.3%
-3.5%
Q4 24
-6.4%
-9.4%
Q3 24
-2.7%
3.5%
Q2 24
2.0%
-36.9%
Net Margin
CLOV
CLOV
CLVT
CLVT
Q1 26
-6.9%
Q4 25
-10.1%
0.5%
Q3 25
-4.9%
-4.5%
Q2 25
-2.2%
-11.6%
Q1 25
-0.3%
-17.5%
Q4 24
-6.6%
-28.9%
Q3 24
-2.8%
-10.5%
Q2 24
2.1%
-46.8%
EPS (diluted)
CLOV
CLOV
CLVT
CLVT
Q1 26
$-0.06
Q4 25
$0.00
Q3 25
$-0.04
Q2 25
$-0.11
Q1 25
$-0.15
Q4 24
$-0.27
Q3 24
$-0.09
Q2 24
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
CLVT
CLVT
Cash + ST InvestmentsLiquidity on hand
$78.3M
Total DebtLower is stronger
$4.3B
Stockholders' EquityBook value
$308.7M
$4.8B
Total Assets
$541.0M
$10.9B
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
CLVT
CLVT
Q1 26
Q4 25
$78.3M
$329.2M
Q3 25
$318.7M
Q2 25
$362.6M
Q1 25
$354.0M
Q4 24
$194.5M
$295.2M
Q3 24
$288.0M
$388.5M
Q2 24
$254.8M
$376.4M
Total Debt
CLOV
CLOV
CLVT
CLVT
Q1 26
$4.3B
Q4 25
$4.3B
Q3 25
$4.4B
Q2 25
$4.5B
Q1 25
$4.5B
Q4 24
$4.5B
Q3 24
$4.6B
Q2 24
$4.6B
Stockholders' Equity
CLOV
CLOV
CLVT
CLVT
Q1 26
$4.8B
Q4 25
$308.7M
$4.8B
Q3 25
$340.9M
$4.9B
Q2 25
$344.2M
$5.0B
Q1 25
$336.1M
$5.0B
Q4 24
$341.1M
$5.1B
Q3 24
$342.2M
$5.5B
Q2 24
$324.9M
$5.6B
Total Assets
CLOV
CLOV
CLVT
CLVT
Q1 26
$10.9B
Q4 25
$541.0M
$11.1B
Q3 25
$559.7M
$11.2B
Q2 25
$575.0M
$11.4B
Q1 25
$583.7M
$11.5B
Q4 24
$580.7M
$11.5B
Q3 24
$653.0M
$12.0B
Q2 24
$674.2M
$12.1B
Debt / Equity
CLOV
CLOV
CLVT
CLVT
Q1 26
0.89×
Q4 25
0.89×
Q3 25
0.90×
Q2 25
0.90×
Q1 25
0.90×
Q4 24
0.88×
Q3 24
0.84×
Q2 24
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
CLVT
CLVT
Operating Cash FlowLast quarter
$-66.9M
$134.7M
Free Cash FlowOCF − Capex
$-69.0M
$78.9M
FCF MarginFCF / Revenue
-14.1%
13.5%
Capex IntensityCapex / Revenue
0.4%
9.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$333.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
CLVT
CLVT
Q1 26
$134.7M
Q4 25
$-66.9M
$159.9M
Q3 25
$12.1M
$181.1M
Q2 25
$5.4M
$116.3M
Q1 25
$-16.3M
$171.2M
Q4 24
$34.8M
$141.3M
Q3 24
$50.0M
$202.9M
Q2 24
$44.8M
$126.2M
Free Cash Flow
CLOV
CLOV
CLVT
CLVT
Q1 26
$78.9M
Q4 25
$-69.0M
$89.2M
Q3 25
$11.4M
$115.5M
Q2 25
$4.8M
$50.3M
Q1 25
$-16.5M
$110.3M
Q4 24
$33.3M
$59.1M
Q3 24
$49.6M
$126.3M
Q2 24
$44.4M
$60.3M
FCF Margin
CLOV
CLOV
CLVT
CLVT
Q1 26
13.5%
Q4 25
-14.1%
14.5%
Q3 25
2.3%
18.5%
Q2 25
1.0%
8.1%
Q1 25
-3.6%
18.6%
Q4 24
9.9%
8.9%
Q3 24
15.0%
20.3%
Q2 24
12.5%
9.3%
Capex Intensity
CLOV
CLOV
CLVT
CLVT
Q1 26
9.5%
Q4 25
0.4%
11.5%
Q3 25
0.1%
10.5%
Q2 25
0.1%
10.6%
Q1 25
0.0%
10.3%
Q4 24
0.5%
12.4%
Q3 24
0.1%
12.3%
Q2 24
0.1%
10.1%
Cash Conversion
CLOV
CLOV
CLVT
CLVT
Q1 26
Q4 25
51.58×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

CLVT
CLVT

Subscription$397.5M68%
Re-occurring$108.6M19%
Transactional$79.4M14%

Related Comparisons